Ron Aldridge | executive |
Matthew Klein | executive |
Eric Pauwels | executive |
Kylie O'Keefe | executive |
Pierre Gravier | executive |
Brooke Schuster Gray | analyst |
Rick Miller | analyst |
Yun Zhong | analyst |
Eric Joseph | analyst |
Lee Hung | analyst |
Brian Abrahams | analyst |
John Peyton Bohnsack | analyst |
David Lebowitz | analyst |
Huidong Wang | analyst |
Kyuwon Choi | analyst |
Alex Nackenoff | analyst |
Joseph Schwartz | analyst |
Good day, and, thank you for standing by. Welcome to PTC Fourth Quarter 2023 Financial Results. [Operator Instructions] Please note that today's conference is being recorded.I would now like to pass the call over to the Senior Director of Investor Relations, Ron Aldridge.
Good afternoon, and thank you for joining us today to discuss PTC Therapeutics' fourth quarter and full-year 2023 corporate update and financial results. I'm joined today by our Chief Executive Officer, Dr.